Chlamydia trachomatis is a global human pathogen causing diseases ranging from blinding trachoma to pelvic inflammatory disease. To explore how innate and adaptive immune responses cooperate to protect against systemic infection with C. trachomatis L2, we investigated the role of macrophages (M) and dendritic cells (DCs) in the stimulation of C. trachomatis-specific CD8 ؉ T cells. We found that C. trachomatis infection of M and DCs is far less productive than infection of nonprofessional APCs, the typical targets of infection. However, despite the limited replication of C. trachomatis within M and DCs, infected M and DCs process and present C. trachomatis CD8 ؉ T cell Ag in a proteasome-dependent manner. These findings suggest that although C. trachomatis is a vacuolar pathogen, some Ags expressed in infected M and DCs are processed in the host cell cytosol for presentation to CD8 ؉ T cells. We also show that even though C. trachomatis replicates efficiently within nonprofessional APCs both in vitro and in vivo, Ag presentation by hematopoietic cells is essential for initial stimulation of C. trachomatis-specific CD8 ؉ T cells. However, when DCs infected with C. trachomatis ex vivo were adoptively transferred into naive mice, they failed to prime C. trachomatis-specific CD8 ؉ T cells. We propose a model for priming C. trachomatis-specific CD8 ؉ T cells whereby DCs acquire C. trachomatis Ag by engulfing productively infected nonprofessional APCs and then present the Ag to T cells via a mechanism of cross-presentation.
C
hlamydia trachomatis is an obligate intracellular bacterial pathogen that causes both genital and ocular disease in humans (1) . C. trachomatis infection of the genital mucosa can result in pathology ranging from mild inflammation to pelvic inflammatory disease and infertility. C. trachomatis can also infect the ocular mucosa and cause blinding trachoma. C. trachomatis is distinguished from other intracellular pathogens by its unique biphasic developmental cycle (2) . The elementary body (EB) 3 is a metabolically inert form of the organism that is responsible for infecting the host cell. Once host cells take up organisms, they are confined to a vacuole known as the inclusion. Within the inclusion, the bacteria are protected from lysosomal fusion and differentiate into the metabolically active reticulate body (RB) form. RBs replicate within the inclusion, converting back into EBs just before cell lysis.
C. trachomatis infection mobilizes all arms of the adaptive immune system. Abs elicited against outer membrane proteins of C. trachomatis aid in blocking attachment and subsequent internalization of the bacteria by host cells (3, 4) . Nevertheless, neutralization of C. trachomatis by Abs provides incomplete protection, and some organisms enter cells. Once organisms have entered host cells and begun developing, clearance of the bacteria requires the activity of T cells. In a number of studies, CD4 ϩ T cells have been shown to play a crucial role in host defense against C. trachomatis (5-8). Because C. trachomatis resides within a vacuole, it was initially thought that proteins derived from the bacteria were excluded from the host cell cytosol. The absence of cytosolic proteins would seem to preclude a major role for CD8 ϩ T cells in clearance of the organism. However, several groups recently have shown that C. trachomatis proteins do, in fact, access the cytosol and elicit CD8
ϩ T cell responses in the host (9 -16) . Both C. trachomatis-specific CD4 ϩ and CD8 ϩ T cells have been cultured in vitro from infected mice (7, 10, 11) . When these C. trachomatis-specific T cells are adoptively transferred into infected mice, they are capable of reducing the number of C. trachomatis EBs recovered from these animals.
These studies demonstrating that C. trachomatis-specific CD8 ϩ T cells are generated following infection are particularly intriguing given that C. trachomatis primarily infects epithelial cells, such as those lining the genital tract and conjunctiva (17, 18) . Although CD4 ϩ T cells typically recognize professional APCs (pAPCs) that express MHC class II molecules on their cell surface, CD8 ϩ T cells are able to recognize all nucleated cell types, including epithelial cells. Therefore, once C. trachomatis enter host epithelial cells, CD8 ϩ T cell responses may play a particularly important role in controlling the replication and spread of the organism. A C. trachomatis CD8 ϩ T cell Ag, Cap1 (16) , has recently been identified. We can now use this Ag as a tool to study the interactions between C. trachomatis and APCs, specifically to determine which cells contribute to the priming of C. trachomatis-specific CD8 ϩ T cells.
Nonprofessional APCs, such as epithelial cells and fibroblasts, have been shown to support the replication of C. trachomatis and are recognized by C. trachomatis-specific CD8 ϩ T cell lines (9, 11, 12, 19) . However, recognition of nonprofessional APCs is not usually sufficient to prime naive CD8 ϩ T cells. Typically, priming of both viral-and bacterial-specific CD8 ϩ T cells requires Ag presentation by hematopoietic cells (20 -22) , including macrophages (M) and dendritic cells (DCs) (23, 24) . However, several groups of investigators have questioned the ability of C. trachomatis to productively infect M and DCs. Early studies of the interaction between murine peritoneal M and C. trachomatis serovars B and L2 indicated that infection either kills M immediately or fails to result in inclusion formation (25, 26) . In contrast, C. trachomatis L2 infection of human monocyte-derived M resulted in bacterial replication, but both normal and atypical inclusions were observed in these cells (27) . These studies suggest that the development of C. trachomatis within M is different from growth within nonprofessional APCs.
Similarly, C. trachomatis development within DCs has also been shown to differ from development within nonprofessional APCs. Ojcius et al. (28) demonstrated that C. trachomatis-containing endosomes fuse with host cell lysosomes in an infected murine DC cell line. However, the aborted developmental cycle of C. trachomatis in these cells did not affect the ability of the infected DCs to be recognized by C. trachomatis-specific CD4 ϩ T cells in vitro. Another study by Matyszak et al. (29) used primary human DCs and did not detect fusion of the C. trachomatis-containing endosomes with lysosomes. However, these investigators found that inclusions were rare and abnormally small within C. trachomatis-infected human DCs. Nevertheless, the authors demonstrated that these C. trachomatis-infected DCs were effective APCs, as measured by their ability to stimulate both CD4 ϩ and CD8 ϩ T cells from patients infected with C. trachomatis. Although these two studies present conflicting data regarding the trafficking of the inclusion in DCs, both studies suggest a role for C. trachomatis-infected DCs in the generation of C. trachomatisspecific T cells.
The conflicting data concerning the ability of C. trachomatis to replicate in M and DCs led us to investigate the role of these cells in stimulating C. trachomatis-specific CD8 ϩ T cells. If C. trachomatis is unable to develop and replicate in M and DCs, there may only be minimal levels of bacterial Ag produced inside these cells that is available for processing and presentation to CD8 ϩ T cells. Because a higher level of Ag presentation is required to prime naive CD8 ϩ T cells than to stimulate effector CD8 ϩ T cells, a low Ag density within M or DCs might prevent these cells from priming C. trachomatis-specific CD8 ϩ T cells. Although the majority of pathogen-specific CD8 ϩ T cell responses require presentation by pAPCs for priming, nonprofessional APCs also appear to be able to prime CD8 ϩ T cells (30, 31) . For example, Kundig et al. (30) used fibroblasts transfected with the glycoprotein of lymphocytic choriomeningitis virus to immunize mice and detected priming of glycoprotein-specific CD8 ϩ T cells. These studies raise the possibility that during C. trachomatis infection, epithelial cells alone might be sufficient for priming a CD8 ϩ T cell response. In this study, we sought to examine the role of M and DCs in the generation of CD8 ϩ T cell responses to C. trachomatis during systemic infection with serovar L2. We first tested whether C. trachomatis productively infects murine M and DCs. If infection of these cell types is poor or aberrant, it is possible that only a limited repertoire and/or amount of C. trachomatis Ag would be presented by these pAPCs to CD8 ϩ T cells. This could alter the ability of infected M and DCs to effectively prime naive CD8 ϩ T cells or to stimulate the effector functions of activated C. trachomatis-specific CD8 ϩ T cells. We report in this study that C. trachomatis is capable of productively infecting primary murine M and DCs, although the infectious yield is much less than that recovered from nonprofessional APCs. Despite their relative inability to support C. trachomatis replication, infected M and DCs are able to stimulate a C. trachomatis-specific CD8 ϩ T cell line in vitro. Likewise, hematopoietic cells, most likely M and DCs, are required to prime a C. trachomatis-specific CD8 ϩ T cell response in a murine model of infection. Nevertheless, we find that in vivo priming of CD8 ϩ T cells is unlikely to be initiated by directly infected pAPCs that appear to express insufficient levels of C. trachomatis Ag. Instead, we hypothesize that for pAPCs to obtain enough C. trachomatis Ag to prime naive CD8 ϩ T cells, they must access Ag expressed in productively infected epithelial cells. 
Materials and Methods

Mice
Growth, isolation, and detection of C. trachomatis
EBs of C. trachomatis serovar L2 434/Bu were propagated within McCoy cell monolayers grown in Eagle's MEM supplemented with 1.5 g/L sodium bicarbonate, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 10% FCS. EBs were released from infected McCoy cells with glass beads and purified by density gradient centrifugation, as described (32) . Aliquots of C. trachomatis were stored at Ϫ80°C in a buffer containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic acid (pH 7.2) (sucrose-phosphate-glutamate freezing media) (33) .
To measure the productivity of C. trachomatis infection in BALB 3T3 cells, bone marrow-derived Ms, and bone marrow-derived DCs, cells were infected for the indicated periods of time and then frozen at Ϫ80°C. Cells were subsequently thawed and sonicated to release viable EBs. Lysates of infected cells were used to infect McCoy cell monolayers and incubated for 36 h to allow the development of inclusions. McCoy cell monolayers were infected in duplicate for each time point. Monolayers were then fixed and stained with a FITC-conjugated anti-C. trachomatis Ab to visualize developing inclusions. For each well, three microscopic fields were chosen at random and the number of inclusion-forming units (IFU)/ field was counted. The mean number of IFU/field was then calculated by averaging the number of IFU/field across duplicate wells. To determine the mean number of IFU/sample, the following calculation was made: mean number of IFU/sample ϭ mean number of IFU/field ϫ lens factor* ϫ dilution factor**. *, Refers to the fraction of the total area of the cell monolayer that is viewed under a particular objective. **, Refers to the fraction of the original sample that actually gets plated onto McCoy cell monolayer. The productivity of infection of each cell type was reported as the ratio of the mean number of IFU recovered from host cells at a given time point (i.e., output IFU) relative to the average number of IFU used to initially infect host cells (i.e., input IFU).
Infection of tissue culture monolayers with C. trachomatis
Before infection, cells were rinsed twice with medium without antibiotics and incubated overnight. To infect cells with C. trachomatis, cells were incubated with bacteria in SPG and centrifuged at 1925 ϫ g at 30°C for 1 h to increase the contact between the bacteria and the tissue culture cells. The multiplicity of infection (MOI) used for each experiment varied and is specifically mentioned in Results. After centrifugation, the inoculum was removed and the cells were incubated for the indicated periods of time at 37°C in medium without antibiotics.
Stimulation and maintenance of C. trachomatis-specific CD8 ϩ T cells
The C. trachomatis-specific H-2 d -restricted CD8 ϩ T cell line 69 was maintained and expanded by weekly stimulation on C. trachomatis-infected J774 cells, as described (11) . T cells specific for the Cap1 139 -147 epitope were stimulated from infected mice, as previously described (16 
Assays for T cell activity
Chromium release assays were used to determine the percent specific lysis of target cells, as previously described (11) . IFN-␥ ELISA was also used to measure T cell activity. Supernatants from the coculture of CD8 ϩ T cells and APCs were collected after 16 h, unless otherwise noted. These supernatants were analyzed for the presence of IFN-␥ using an IFN-␥ Minikit (Pierce, Woburn, MA), according to the manufacturer's instructions.
IFN-␥ ELISPOT
Spleens from experimental mice were harvested, and the RBC were lysed with ammonium/chloride potassium (ACK) lysis buffer (34) . The splenocytes were counted and added at a concentration of 5 ϫ 10 5 or 1 ϫ 10 5 cells/well to nitrocellulose-backed 96-well plates previously coated with rat anti-mouse IFN-␥ Ab (18181D; BD Biosciences, San Jose, CA). Each well also contained 1 ϫ 10 5 irradiated P815 stimulator cells that had been previously pulsed with Cap1 139 -147 peptide. The plates were incubated for 24 -28 h and then washed and treated with biotinylated rat anti-mouse IFN-␥ Ab (XMG1.2; BD Biosciences). After an additional 18 h, the plates were washed again, and streptavidin-HRP (BD Biosciences) was added. The plates were developed with 1 mg/ml 3, 3Ј-diaminobenzidine tetrahydrochloride dyhrate (Bio-Rad, Hercules, CA) in 50 mM Tris (pH 7.9).
Isolation of bone marrow-derived M and DCs
Femurs and tibias were removed from mice and flushed with RP10. After washing the bone marrow cells once, the total number of cells was counted. For the culture of M, ϳ1 ϫ 10 6 cells per plate were seeded into 100-mm nontissue culture-treated petri dishes. M were cultured in RPMI 1640 medium containing 20% FCS, L-glutamine, penicillin, streptomycin, and 20% L929 cell-conditioned medium. The medium was replaced on day 4, and cells were used on day 7. DCs were cultured, as described by Lutz et al. (35) . Briefly, 5 ϫ 10 6 bone marrow cells were cultured in RP10 supplemented with J558L cell-conditioned medium. J558L is a GM-CSF-producing mouse M-like cell line that was generously provided by I. Mellman (Yale University, New Haven, CT). The medium was supplemented on day 3, and the DCs were used on day 6. The purity of the DC cultures was assessed by flow cytometry, as described below. To obtain mature DCs for use in experiments, the DCs were further incubated in culture medium containing 5 g/ml purified LPS (Sigma-Aldrich, St. Louis, MO) for 16 h.
Paraformaldehyde fixation of APCs
For experiments in which APCs were fixed before their use in assays, the cells were distributed into 96-well plates. After infection and incubation, cells were centrifuged for 10 min at 260 ϫ g and washed once with RPMI 1640. Cells were fixed with a 1% paraformaldehyde solution for 10 -15 min at room temperature. The cells were then washed twice in RPMI 1640 before their use in assays.
Flow cytometric analysis of DC culture purity and maturity
Cells were surface stained and analyzed using standard protocols (36) . Abs specific for the following molecules were obtained from BD Biosciences: DC/M markers, CD11b (M1/70) and CD11c (HL3); DC activation markers, CD86 (GL1), CD80 (16-10A1), and CD40 (HM40-3); and a MHC class II molecule: I-A b (AF6-120.1) or I-A d (39-10-8) . Cells were stained, washed, and resuspended in HBSS containing 1.0% BSA and 0.1% NaN 3 .
Magnetic cell separation of DCs
For adoptive transfer studies, DCs were purified using the MACS magnetic bead system, according to the manufacturer's instructions (Biotech International, Auburn, CA). Cells were washed and resuspended in PBS supplemented with 0.5% BSA. Before separation, nonspecific binding of the microbeads by Fc receptors expressed by M was inhibited by incubating the cells with 1 g of Fc block reagent (BD Biosciences) per 1 ϫ 10 6 cells for 15 min at 4°C. After blocking, 100 l of CD11c microbeads per 1 ϫ 10 8 cells was added, and the mixture was incubated for 15 min at 6 -12°C. The mixture was then washed twice in PBS/0.5% BSA and resuspended in 500 l of PBS/0.5% BSA per 1 ϫ 10 8 cells. Magnetic separation was initiated by application of the bead-labeled cells to a column attached to a MACS separator magnet. After washing the column, the column was removed from the magnetic field, and positively labeled cells were flushed from the column. FACS analysis of these cells using anti-CD11c and antiCD11b Abs showed these cells to be Ն85% DCs.
Treatment of cells with chemical inhibitors of Ag processing
APCs were infected with C. trachomatis and incubated for 16 -20 h to allow time for C. trachomatis CD8 ϩ T cell Ags to be expressed before inhibitors were added. The following inhibitors were used: Z-L 3 -VS at a concentration of 50 M (a gift from H. Ploegh, Harvard Medical School, Boston, MA) and bafilomycin A1 at a concentration of 1 M (Calbiochem, San Diego, CA). Both inhibitors were dissolved in DMSO and then diluted 100-fold into the cell cultures. APCs were incubated with inhibitor or DMSO alone as a negative control at 37°C for an additional 4 h. After incubation, the cells were washed thoroughly to insure the removal of both the DMSO and any unincorporated inhibitor.
Generation of radiation bone marrow chimeras
CB6 mice were irradiated with two doses of 600 rad separated by 3 h. Irradiated mice were reconstituted with 6 ϫ 10 6 bone marrow cells from the indicated mice on the following day. To avoid lysis of donor bone marrow cells by NK cells in the recipient, 10 l of anti-asialo GM1 Ab (Wako Chemicals, Osaka, Japan) was injected i.p. into recipient mice on the day of bone marrow transplant and 3 days after bone marrow reconstitution. To assess the level of chimerism at the time of infection, peripheral blood cells were analyzed by flow cytometry for the presence of donorderived cells. Mice were anesthetized with isofluorane, and their blood was collected retraorbitally. RBC were lysed with ACK lysis buffer, and the remaining white blood cells were stained with anti-TCR-␤ (H57-597; BD Biosciences) Abs (to evaluate the T cell phenotype) and anti-CD11b (M1/ 70; BD Biosciences) Abs (to evaluate the M and DC phenotype). The leukocyte populations were analyzed by flow cytometry for their expression of the MHC allele of the bone marrow donor mice using anti-H-2K
b (AF6-88.5; BD Biosciences) Abs. All animals used in experiments displayed 85-97% levels of chimerism, as measured by the expression of the donor cell MHC allele on peripheral blood cells from the chimeric mice. Experiments were performed from 8 wk to 6 mo after irradiation and reconstitution. All experimental groups were age matched.
Tetracycline treatment of mice
A total of 2 mg of tetracycline was administered i.p. 24 h before infection and then every 24 h until the end of the experiment (37) .
In vitro priming assay
Splenocytes from naive or C. trachomatis-immune BALB/c mice were depleted of RBC using ACK lysis buffer. To enrich for T cells, leukocytes were loaded onto a mouse T cell enrichment column (R&D Systems, Minneapolis, MN). Following enrichment, the T cell populations were labeled with 5 M CFSE, as previously described (38) . Briefly, cells were resuspended in PBS/0.1% BSA at a concentration of 10 7 cells/ml. CFSE was added to cells to a final concentration of 5 M, and cells were labeled for 10 min at 37°C. After labeling, the cells were washed with PBS/0.1% BSA and resuspended in RP10. The labeled T cells were cocultured with the appropriate APC population at an E:T ratio of 10:1. After 3 days of in vitro stimulation, the cultures were harvested and stained with anti-CD8 (53-5.8; BD Biosciences) and anti-TCR-␤ (H57-597; BD Biosciences) Abs before analysis by flow cytometry. 
Cross-presentation assay
Results
C. trachomatis infection of M and DCs is less productive than infection of nonprofessional APCs
It is well established that C. trachomatis replicates efficiently within nonprofessional APCs (39) . To determine how the productivity of infection of M and DCs compares with that of nonprofessional APCs, we infected BALB/c DCs, BALB/c M, and BALB/3T3 fibroblasts cells with C. trachomatis at a MOI of 10:1. Productive C. trachomatis infection of a host cell was defined as the ability of bacteria to enter the host cell, develop into RBs, replicate, and then convert back into the infectious EB form. We assayed the ability of C. trachomatis to replicate in the three cell types by comparing the ratio of the number of EBs that exited the infected cell population for every EB that entered these cells. In all three cell types, we observed a reduction in the number of IFU recovered soon after infection (Fig. 1) . This was expected because at these time points the bacteria had differentiated into RBs, the noninfectious form of the organism that could not be measured by these assays. As anticipated, there was a significant increase in the number of IFU recovered from C. trachomatis-infected BALB/ 3T3 fibroblasts over time (Fig. 1A) . In contrast, the number of EBs recovered from DCs and M was dramatically lower (Fig. 1, B and C). Increasing the MOI to 25:1 for DCs and M resulted in only minimal increases in the productivity of infection (data not shown). It is not clear whether the low productivity of infection in M and DCs was simply the result of only a small number of cells being infected or the poor development of C. trachomatis-containing inclusions within a large number of infected cells. Regardless, we find that C. trachomatis infection is much more productive in nonprofessional APCs than in M and DCs.
C. trachomatis-specific CD8 ϩ T cells recognize infected M and DCs
Because the low level of C. trachomatis replication in M and DCs may result in undetectable levels of C. trachomatis Ag presentation by these cells, we tested whether the previously identified C. trachomatis-specific CD8 ϩ T cell line 69 (11) could recognize C. trachomatis-infected M and DCs (Fig. 2) . As expected, infected nonprofessional APCs, which support high levels of bacterial replication (Fig. 1A) , consistently stimulated IFN-␥ secretion by the C. trachomatis-specific CD8 ϩ T cell line 69 ( Fig. 2A) . In contrast, C. trachomatis-infected M, in which bacterial replication was limited (Fig. 1C) , stimulated ϳ10-fold less IFN-␥ secretion from the T cell line than did infected nonprofessional APCs (Fig. 2C) . Interestingly, despite our finding that DCs were the least productively infected cell type (Fig. 1B) , these cells stimulated the greatest amount of IFN-␥ secretion from the C. trachomatis-specific CD8 ϩ T cell line 69 (Fig. 2B) . These results show the enhanced ability of DCs to process and present Ag, even overcoming the limitation imposed by modest C. trachomatis replication.
Processing of C. trachomatis Ag is proteasome dependent
One aspect of Ag presentation that distinguishes M and DCs from nonprofessional APCs is their ability to process both endogenous and exogenous Ags for presentation on MHC class I. The recognition of infected nonprofessional APCs by C. trachomatisspecific CD8 ϩ T cells indicates that some C. trachomatis Ag accesses the host cell cytosol for processing by the endogenous MHC class I processing pathway (11) . This pathway is dependent on the host cell proteasome to digest protein Ags into peptide epitopes within the host cell cytosol. However, in M and DCs, Ags also can be processed through an endosomal pathway termed the exogenous MHC class I processing pathway (40) . CD8
ϩ T cell Ags processed within the endosomal compartment can be processed by the acid proteases that also generate the peptides that bind MHC class II molecules. We investigated whether the vacuolar localization of C. trachomatis during development might allow Ags from this pathogen to be processed by the endosomal, exogenous MHC class I processing pathway in M and DCs.
To examine the relative contribution of the exogenous vs the endogenous MHC class I processing pathways to the processing of C. trachomatis Ag in infected cells, we used chemical inhibitors to selectively block the digestion of C. trachomatis proteins into peptide epitopes in either the cytosolic or endosomal compartments. To block presentation by the endogenous pathway, we used the At the indicated times after infection, the cells were freeze thawed and subsequently sonicated to release intracellular EBs. These lysates were then used to infect McCoy cell monolayers. Duplicate wells were infected for each sample. McCoy cell monolayers were fixed 36 h after infection and stained for inclusions using a FITC-conjugated Ab specific for C. trachomatis. The number of inclusions per microscopic field was counted for each time point, and the average IFU recovered for each sample were calculated, as described in Materials and Methods. The fold difference in the number of IFU recovered at each time point relative to the input IFU was calculated by dividing the average number of IFU per sample at the specified time point (i.e., output IFU) by the number of IFU present at t ϭ 0 h postinfection (i.e., input IFU). Sample variation across duplicate wells never resulted in a value for the fold difference that was greater than 0.04 for DCs, 1.0 for M, or 20 for BALB/3T3 cells. These differences are not significant given the levels of infection within each individual cell type. The data shown are representative of three separate experiments. The purity of both the DC and M cells used in this experiment was Ͼ90%.
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PRIMING OF Chlamydia-SPECIFIC CD8 ϩ T CELL RESPONSES trileucine peptide vinyl sulfone proteasome inhibitor, Z-L 3 -VS. To inhibit the exogenous Ag-processing pathway, we used bafilomycin A1, a specific inhibitor of the vacuolar-type proton ATPase that prevents acidification of the endosomal compartment. As shown in Fig. 3A , Z-L 3 -VS treatment completely inhibited the ability of C. trachomatis-infected BALB/3T3 cells to stimulate the C. trachomatis-specific CD8 ϩ T cell line 69. This finding was consistent with established paradigms of how CD8 ϩ T cell Ags are processed by the endogenous MHC class I pathway in nonprofessional APCs (40) . Treatment with the proteasome inhibitor also completely blocked C. trachomatis CD8 ϩ T cell Ag presentation by infected DCs and M (Fig. 3, B and C) . These data indicate that processing of C. trachomatis CD8 ϩ T cell Ag is proteasome dependent. In contrast, treating C. trachomatis-infected DCs and M with bafilomycin A1 failed to block their recognition by line 69 (Fig. 3 , B and C). As a positive control to test the efficacy of bafilomycin A1 in these assays, we demonstrated the ability of this drug to block anthrax toxin-mediated CD8 ϩ T cell epitope delivery to the cytosol, a process that is dependent upon the acidic pH of the endosome (data not shown) (41) . These results suggest that in M and DCs, C. trachomatis CD8 ϩ T cell epitopes are not generated inside of the endosomal compartment. However, it is also possible that the amount of C. trachomatis CD8 ϩ T cell epitopes generated within this compartment is too low to stimulate IFN-␥ secretion from C. trachomatis-specific CD8 ϩ T cells.
Hematopoietic cells are required for priming Cap1-specific CD8 ϩ T cells
Although pAPCs are believed to prime the majority of CD8 ϩ T cells, nonhematopoietic cells, like fibroblasts, have been shown to prime some viral-and tumor-specific CD8 ϩ T cell responses (30, 31) . We found that C. trachomatis infection of fibroblasts is very productive in vitro (Fig. 1A) , and others have observed that epithelial cells are the major reservoir of C. trachomatis infection in vivo (18) . Because high Ag level has been shown in some cases to overcome the requirement for costimulation during priming of CD8 ϩ T cells (42), we hypothesized that infected nonhematopoietic cells might be sufficient for priming CD8 ϩ T cells specific for the C. trachomatis CD8 ϩ T cell epitope, Cap1 139 -147 . We used radiation bone marrow chimeras to differentiate between the ability MHC allele on nonhematopoietic cells. As a result, in the B63 CB6 chimeric mice, Cap1 139 -147 can only be presented on nonhematopoietic cells. Mock chimeras reconstituted with CB6 bone marrow (CB63 CB6) were also generated to control for any unexpected effects of chimerism.
All chimeric mice were infected i.p. with 1 ϫ 10 8 IFU of C. trachomatis. The infected mice were then allowed to recover for 2 wk before their spleens were removed and cultured with BALB/c splenocytes pulsed with Cap1 139 -147 peptide. After 5 days of culture in vitro, the splenocytes from each chimera were tested in a cytotoxicity assay (Fig. 4A) . We found that T cells from the BALB/c3 CB6 and CB63 CB6 chimeras specifically recognized P815 cells pulsed with the Cap1 139 -147 peptide. This outcome was expected because both hematopoietic and nonhematopoietic cells can present the Cap1 139 -147 peptide in these chimeras. However, T cells from the B63 CB6 chimera, in which only nonhematopoietic cells presented Cap1, were not able to specifically lyse Cap1 139 -147 peptide-pulsed P815 cells. These findings suggest that Cap1 must be presented on hematopoietic cells to stimulate Cap1-specific CD8 ϩ T cells. To confirm these results, we also quantified the level of Cap1 139 -147 -specific T cell priming in the chimeras using IFN-␥ secretion as a measure of CD8 ϩ T cell effector function. The chimeras were infected i.p. with 1 ϫ 10 8 IFU of C. trachomatis as in the previous experiment. After 7 days, their spleens were removed, and the number of Cap1 139 -147 -specific CD8 ϩ T cells primed following infection was quantified using an IFN-␥ ELISPOT assay. Consistent with our observation from the cytotoxicity assay, Cap1 139 -147 -specific CD8 ϩ T cells were detected in the splenocytes from the C. trachomatis-infected BALB/c3 CB6 and CB63 CB6 chimeras, but not in the B63 CB6 chimeras (Fig. 4B) . Again, these results confirm that hematopoietic APCs are required to prime Cap1 139 -147 -specific CD8 ϩ T cells. An alternative explanation for the inability to detect Cap1 139 -147 -specific CD8 ϩ T cells in the B63 CB6 chimeras is that precursors for these T cells simply did not develop in these mice. To determine whether Cap1 139 -147 -specific T cell precursors exist and can be primed in the B63 CB6 chimeras, Cap1 139 -147 peptide-pulsed BALB/c DCs were injected into these mice as a source of hematopoietic cells expressing the H-2 d molecule. Using an IFN-␥ ELISPOT, we detected priming of Cap1 139 -147 -specific CD8 ϩ T cells in both the BALB3 CB6 and B63 CB6 chimeras after immunization with Cap1 139 -147 peptide-coated BALB/c DCs (Fig. 4C) . We believe that more Cap1-specific CD8 ϩ T cells were primed in the BALB3 CB6 chimeras because the injected DCs can serve as both APCs and as sources of Cap1 peptide for resident H-2 d pAPCs in these mice. These results support our conclusion that presentation by hematopoietic cells is essential for Cap1-specific CD8 ϩ T cell priming during C. trachomatis infection.
Adoptive transfer of C. trachomatis-infected hematopoietic cells does not result in priming of Cap1 139 -147 -specific CD8
ϩ T cells
Because there appeared to be a requirement for hematopoietic cells in priming Cap1 139 -147 -specific CD8 ϩ T cells in vivo, we sought to identify the hematopoietic cell type responsible for priming these T cells. Because M and DCs are the typical APCs thought to prime CD8 ϩ T cells, we adoptively transferred C. trachomatisinfected BALB/c M or DCs into B63 CB6 chimeric mice and evaluated the generation of Cap1 139 -147 -specific CD8 ϩ T cells using an IFN-␥ ELISPOT assay. Surprisingly, neither C. trachomatis-infected DCs nor infected M primed Cap1 139 -147 -specific CD8 ϩ T cells in the B63 CB6 chimeras (Fig. 5) . In contrast, C. trachomatis-infected DCs and M primed Cap1 139 -147 -specific CD8 ϩ T cells in the control CB63 CB6 chimeric mice (Fig. 5 ). This discrepancy could be explained in one of two ways. The most obvious explanation is that the C. trachomatis-infected M and 
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PRIMING OF Chlamydia-SPECIFIC CD8 ϩ T CELL RESPONSES DCs are directly priming Cap1 139 -147 -specific CD8 ϩ T cells in the CB63 CB6 mice. This explanation seems unlikely because the same C. trachomatis-infected M and DCs failed to prime Cap1-specific T cells in the B63 CB6 chimeras. Alternatively, the infected M and DCs may have lysed in vivo and released EBs that subsequently infected the CB63 CB6 mouse directly. To determine whether the priming of Cap1 139 -147 -specific CD8 ϩ T cells following adoptive transfer of C. trachomatis-infected M and DCs in the CB63 CB6 mice was the result of spread of infection from the transferred pAPCs, we repeated the experiment again while administering the antibiotic tetracycline to the recipient mice. Control mice also received C. trachomatis-infected M or DCs, but were injected with PBS instead of tetracycline. We found that administration of tetracycline to CB63 CB6 mice eliminated priming of Cap1 139 -147 -specific CD8 ϩ T cells following immunization with C. trachomatis-infected M and DCs (Fig. 5) . Because blocking the spread of infection prevented Cap1-specific T cell priming in these mice, we conclude that adoptive transfer of C. trachomatis-infected M or DCs is not sufficient for priming Cap1 139 -147 -specific CD8 ϩ T cells.
C. trachomatis-infected hematopoietic cells are unable to stimulate naive CD8 ϩ T cells in vitro
Our observation that C. trachomatis-infected M did not directly prime Cap1 139 -147 -specific CD8 ϩ T cells in vivo (Fig. 5) was not surprising considering both the poor ability of C. trachomatis to replicate within these cells and their weak stimulation of C. trachomatis-specific CD8 ϩ T cells in vitro (Figs. 1C and 2C) . However, because we found that C. trachomatis-infected DCs were much better than M in stimulating C. trachomatis-specific CD8 ϩ T cells in vitro (Fig. 2B) , we anticipated that DCs might be able to prime these T cells in vivo. Our inability to detect priming of Cap1 139 -147 -specific CD8 ϩ T cells by C. trachomatis-infected DCs could simply be attributed to our failure to transfer sufficient numbers of infected DCs to the chimeras. Because transfer of greater numbers of DCs proved lethal to the animals, we decided to address this concern by performing an in vitro priming assay in which we investigated the ability of C. trachomatis-infected DCs to stimulate proliferation of naive CD8 ϩ T cells. This assay allowed us to significantly increase the E:T ratio of naive CD8 ϩ T cells to C. trachomatis-infected DCs.
We measured the proliferation of CD8 ϩ T cells using a CFSE dye dilution assay. Naive BALB/c splenocytes were CFSE labeled and coincubated with DCs either externally loaded with Cap1 139 -147 peptide or infected with C. trachomatis. DCs that were pulsed with Cap1 139 -147 peptide were also pretreated with LPS to up-regulate surface expression of costimulatory molecules. As shown in Fig. 6C , DCs treated with LPS and pulsed with 10 M Cap1 139 -147 peptide stimulated proliferation of naive CD8 ϩ T cells. In contrast, C. trachomatis-infected DCs failed to stimulate proliferation of naive CD8 ϩ T cells (Fig. 6A) . As a positive control, we demonstrated that effector CD8 ϩ T cells from C. trachomatis-immune mice proliferated in response to both 10 M Cap1 139 -147 peptide-coated DCs (Fig. 6D) and C. trachomatisinfected DCs (Fig. 6B) .
The observation that C. trachomatis-infected DCs fail to prime CD8 ϩ T cells in vitro is surprising and raises the possibility that there is something inherently altered in the C. trachomatis-infected DC that precludes its ability to stimulate naive CD8 ϩ T cells. It is possible that C. trachomatis-infected DCs either present inadequate amounts of C. trachomatis Ag or express insufficient levels of costimulatory molecules. To address the issue of Ag presentation, we titrated the amount of peptide used to externally load LPS-matured DCs. Reducing the levels of peptide by even 10-fold eliminated the in vitro priming of naive CD8 ϩ T cells (Fig. 6, C , E, and G), but did not prevent the recognition of these peptidecoated DCs by effector CD8 ϩ T cells from a C. trachomatisimmune spleen (Fig. 6, D, F, and H) . This result suggests that the level of Ag presented by C. trachomatis-infected DCs may be too low to prime naive CD8 ϩ T cells but is sufficient to stimulate effector CD8 ϩ T cells. Costimulation is also important in the activation of naive CD8 ϩ T cells, as determined by the inability of Cap1 139 -147 peptidecoated immature DCs to prime Cap1 139 -147 -specific CD8 ϩ T cells (data not shown). As shown in Fig. 7 , A-C, C. trachomatis infection of DCs results in their up-regulation of surface expression of MHC class I and II molecules as well as the accessory signaling molecule, CD40. We observed similar levels of up-regulation of these surface molecules after LPS treatment of immature DCs (Fig.  7, A-C) . However, there was considerably less up-regulation of surface expression of the costimulatory molecule CD86 after C. trachomatis infection compared with the up-regulation observed following LPS treatment of the DCs (Fig. 7D ). More dramatically, following C. trachomatis infection, DCs fail to up-regulate expression of the costimulatory molecule CD80 (Fig. 7E) . Taken together, these results suggest that a combination of low Ag level and impaired up-regulation of costimulatory molecule expression contributes to the inability of directly infected DCs to prime a C. trachomatis-specific CD8 ϩ T cell response. 
C. trachomatis Ag can be cross-presented by DCs in vitro
Our findings suggest that not only does C. trachomatis replicate poorly within DCs, but it also inhibits DC maturation. These observations led us to question how DCs could obtain sufficient C. trachomatis Ag to stimulate naive CD8 ϩ T cells without suffering from the negative effects of infection. One mechanism by which DCs could acquire C. trachomatis Ag without direct infection is to phagocytose infected cells. (Fig. 8B ) more efficiently than they cross-presented infected epithelial cells (Fig. 8A) or M (Fig. 8C) . It is possible that DCs serve as the best Ag donors in this assay not because of Ag quantity, but because it is easier to engulf nonadherent DCs than to engulf adherent epithelial cells or M. These data suggest that cross-presentation of C. trachomatis-infected cells is one mechanism by which DCs may stimulate C. trachomatis-specific CD8 ϩ T cells.
Discussion
In this study, we show that hematopoietic cells are required for initiating a CD8 ϩ T cell response in vivo during systemic infection with C. trachomatis serovar L2. We further observed that C. trachomatis-infected DCs are much more effective than infected M or nonprofessional APCs at stimulating a C. trachomatis-specific CD8 ϩ T cell line in vitro. However, although infected DCs are recognized by established T cell lines, they failed to stimulate either the proliferation of naive CD8 ϩ T cells in vitro or the generation of Ag-specific CD8 ϩ T cells in vivo following adoptive transfer. We attributed the inability of infected DCs to stimulate naive CD8 ϩ T cells to two factors: incomplete DC maturation following C. trachomatis infection and poor replication of C. trachomatis within DCs. Because directly infected DCs appear to present insufficient levels of C. trachomatis Ag and costimulatory molecules to CD8 ϩ T cells, we propose that during infection naive CD8 ϩ T cells are stimulated by DCs that are cross-presenting Ag generated in productively infected epithelial cells.
Our finding that C. trachomatis infection of DCs inhibits the up-regulation of CD80 and CD86 on the DC cell surface is particularly notable. One interpretation of this weak costimulatory molecule expression is that C. trachomatis exploits this mechanism as a way of subverting the adaptive immune response. Several other pathogens have already been shown to modulate the T cell costimulatory pathway to prevent the development of a pathogen-specific adaptive immune response (45) . One example is a recent study in which an immunosuppressive variant clone of lymphocytic choriomeningitis virus reduced expression of MHC class I and II, CD40, CD86, and CD80 on the surface of infected DCs (46) . Although our study is one of the first to examine the effect of C. trachomatis infection on costimulatory molecule expression by pAPCs, there are several examples in the literature of strategies presumably used by C. trachomatis to evade the host immune response. C. trachomatis infection of the human epithelial cell line, HeLa, renders these cells resistant to apoptosis induction by CD8 ϩ T cell effector molecules such as granzyme B and perforin (47) . Furthermore, infection of HeLa cells with C. trachomatis also results in the degradation of transcription factors responsible for IFN-␥-inducible MHC class I and II expression (48 -50) . Although current evidence supporting a role for immune modulation following C. trachomatis infection derives exclusively from in vitro data, it is provocative to imagine that such modulation may also be occurring during in vivo infection. In fact, there is a growing appreciation for the in vivo relevance of these putative immune evasion strategies given the observation that a number of humans infected with C. trachomatis never establish long-lasting immunity to the organism (51) . If inhibition of DC maturation occurs or infected cells have increased resistance to apoptosis induction in vivo, full activation of a protective anti-C. trachomatis T cell response may be compromised.
Nevertheless, despite any immune evasion by the bacteria, protective CD8 ϩ T cells are generated during C. trachomatis infection (11) and DCs are likely to be the APCs responsible for initial stimulation of CD8 ϩ T cells. One way that DCs avoid the negative effects of direct microbial infection and still access microbial Ag is by cross-presenting Ag obtained from other infected cells. The phenomenon of cross-priming is believed to be particularly important during infections with pathogens that either avoid infection of DCs or induce apoptosis of infected DCs (52, 53) . In this study, we show that DCs can obtain C. trachomatis Ag by phagocytosing C. trachomatis-infected epithelial cells. This Ag is then processed and presented to CD8 ϩ T cells. Cross-presentation may be especially important during C. trachomatis infection not only because C. trachomatis infection suppresses DC maturation, but also because the bacteria do not replicate well within DCs. This poor replication is likely to restrict the level of C. trachomatis Ag available for presentation by DCs, and thereby limit their ability to prime CD8 ϩ T cells. In contrast, C. trachomatis replicates robustly within nonprofessional APCs such as epithelial cells. Therefore, infected epithelial cells could serve as a rich source of bacterial protein for cross-presentation by DCs.
The observations in this study join a growing body of literature supporting a critical role of the DC in eliciting protective anti-C. trachomatis immunity. Su et al. (54) demonstrated that the adoptive transfer of bone marrow-derived DCs pulsed ex vivo with nonviable C. trachomatis induced protective immunity comparable to that induced by live C. trachomatis infection. The use of nonviable C. trachomatis naturally focused this and later studies on the CD4 ϩ T cell response to C. trachomatis (55) . The CD8 ϩ T cell response remained unobserved in these studies because cytosolic localization of protein Ags was thought to be required for stimulating CD8
ϩ T cells, and only live organisms can secrete proteins into the host cell cytosol or into the C. trachomatis inclusion membrane. By using viable bacteria in our studies, we were able to examine the interaction between DCs and C. trachomatis that leads to the generation of a C. trachomatis-specific CD8 ϩ T cell response. Our most intriguing observation that DCs can cross-present C. trachomatis-infected cells expands the potential repertoire of CD8 ϩ T cell Ags. These results suggest that CD8 ϩ T cells can be generated against C. trachomatis Ags that are secreted into the host cytosol as well as Ags that remain confined to the inclusion. However, it is important to recognize that only those Ags that have access to the cytosol during epithelial cell infection will provoke the critical functions of effector CD8 ϩ T cells. This distinction is particularly relevant when considering the development of vaccines against C. trachomatis. Incorporating C. trachomatis Ags that access the host cell cytosol into experimental vaccines should prove most effective at stimulating protective CD8 ϩ T cell immunity. This study provides further evidence of the complexity involved in studying how a protective immune response is generated against a microbial pathogen. Much of the focus of C. trachomatis vaccine development has been on the CD4 ϩ T cell response because these cells play a major role during natural infection (5) (6) (7) (8) . This study suggests that stimulation of the CD8 ϩ T cell response could be inhibited during natural infection. This could underestimate the importance of CD8 ϩ T cells as effectors during a protective immune response to C. trachomatis infection. Therefore, vaccines that stimulate C. trachomatis-specific CD4 ϩ T cell responses might greatly benefit from supplementing the response with Ags designed to stimulate CD8 ϩ T cells. Although there is much that can be learned from the natural immune response to C. trachomatis, immune-related pathology is also a serious consequence of chronic infection. As a result, we must learn from both the successes and failures of the natural response to C. trachomatis infection to develop a vaccine that can provide sterilizing immunity against this pathogen.
